GlassScriptPhysician profile
Todd James White
NPI 1134199615
$3,450.21
in general payments reported to CMS, 2019-2025
34 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $374 · 2021: $251 · 2022: $221 · 2023: $246 · 2024: $844 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $620.66 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $397.78 | 2019-2024 | Repatha, Tepezza, Otezla |
| Cequr Corporation | $336.78 | 2024-2025 | Cequr Simplicity |
| Corcept Therapeutics | $286.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $224.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $201.03 | 2019-2024 | |
| Lilly USA, LLC | $199.57 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $138.13 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $111.35 | 2020-2023 | Pomalyst |
| Janssen Pharmaceuticals, INC | $99.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $97.65 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genentech USA, INC. | $96.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.41 | 2019-2020 | |
| Amarin Pharma, INC. | $67.92 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.66 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.40 | 2019 | |
| Abbott Laboratories | $42.14 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $34.32 | 2019 | |
| Dexcom, INC. | $32.27 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $29.91 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $27.97 | 2019-2024 | |
| Pfizer INC. | $26.60 | 2019 | |
| Shire North American Group INC | $26.48 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.19 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $21.14 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.19 | 2024 | Voquezna |
| Radius Health, INC. | $17.81 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.44 | 2024 | Opsumit, Uptravi |
| Ironshore Pharmaceuticals INC. | $17.29 | 2019 | |
| Acclarent, INC | $16.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2023 | Livalo |
| Regeneron Healthcare Solutions, INC. | $13.22 | 2019 | |
| Circassia INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.